Following the discovery of erythroblastic oncogene B2 (ERBB2) gene amplification in breast cancer, the human epidermal growth factor receptor 2 (HER2) has emerged as an attractive target for antibody therapies [3]. Here, ERBB2 is linked to breast cancer.